# Evidence-verification disposition

Verification scope: the two candidate issues returned by the arithmetic/statistical screens. Only supplied DOC-001 and DOC-004 were used. This is the sole verification stage.

## Candidate V-01 — Figure 2 risk/event display

- **Disposition: Uncertain (not forwarded as a final issue).**
- **Evidence:** DOC-001, `jama_combes_2025_oi_250087_1766516490.94011.pdf`, PDF p. 6 (journal p. 65), Figure 2 lists levosimendan at day 5 as 88 “at risk” and 36 “with event” (randomized N=101), and placebo as 76 and 41 (N=104). Straight additions exceed N. Similar additions exceed N at days 10 and 15.
- **Why not accepted:** Figure 2 provides no definition of “No. of patients with event” or the displayed risk-set convention for its competing-risk cumulative-incidence analysis. Therefore the supplied material cannot establish that the two rows are disjoint participant counts. The usual disjoint-count rule is an inference, not an explicitly stated reporting rule here. The endpoint partitions in the same document reconcile: Table 2 yields 69+15+15+2=101 and 71+21+12=104.
- **Missing evidence:** figure-generation definition/data dictionary or author clarification of the “with event” and “at risk” rows. A human can check the original plotting data or caption source; confirmation that the rows represent cumulative unique events and a standard risk set would support the candidate, whereas a non-disjoint row definition would resolve it.

## Candidate V-02 — Day-30 MACE definition/count

- **Disposition: Accepted.**
- **Category:** Cross-document inconsistency / Statistical reporting inconsistency.
- **Severity:** Moderate.
- **Reported definition:** DOC-001, `jama_combes_2025_oi_250087_1766516490.94011.pdf`, PDF p. 3 (journal p. 62), Methods—Outcomes: “major adverse cardiovascular events (death, heart transplant, escalation to need for left ventricular assist device, stroke, dialysis, or heart failure rehospitalization) at days 30 and 60”.
- **Reported result:** DOC-004, `joi250087supp3_prod_1766516490.97011.pdf`, PDF p. 5, eTable 3, Placebo column: day-30 MACE 36/104 (34.6%); dialysis by day 30 38/104 (36.5%). DOC-004 PDF p. 13, eFigure 4 repeats 36 day-30 placebo events but defines MACE without dialysis.
- **Direct comparison and calculation:** If dialysis is a component of the stated composite, every dialysis case must be a MACE case: n(MACE) >= n(dialysis). Reported values give 36 - 38 = -2 participants (and 34.6% < 36.5%). Counts are integers, so no rounding tolerance can resolve the contradiction.
- **Bounded impact:** under the DOC-001 definition, at least two placebo dialysis cases are absent from the reported 36-person day-30 MACE composite. The supplied package cannot determine whether dialysis was wrongly included in the main-text definition or omitted from the composite derivation; therefore the definition, count, risk difference/RR, and eFigure 4 curve are not jointly verifiable.
- **Human verification:** (1) confirm the DOC-001 definition on PDF p. 3; (2) confirm both eTable 3 placebo counts on DOC-004 PDF p. 5; (3) apply the component-nesting rule; (4) confirm eFigure 4’s definition/count on DOC-004 PDF p. 13; (5) check the authors’ intended composite specification and participant-level derivation. Excluding dialysis resolves nesting only by confirming a definition error; including it requires corrected composite reporting.
